It is with great sadness that we share the passing of Michael L. Shamie, Founder, CEO and President of Avatar Corporation, who died in the early morning on Monday, August 24.
The Society of Chemical Manufacturers & Affiliates (SOCMA) is pleased to announce the addition of five more companies to the association, expanding the total number of new members to 16 in the first three quarters of 2020. SOCMA’s Board of Governors last week approved chemical manufacturer Sofix and service providers Anchin, New York Center for Innovation, POWER Engineers and Rockwell Automation.
Humanigen, a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper response called ‘cytokine storm,’ and Lonza today announced a strategic collaboration to expand the manufacturing capacity for lenzilumab, currently in Phase 3 clinical trials for COVID-19, in advance of potential Emergency Use Authorization in 2020 and subsequent commercialization.
Lonza and Sheba Medical Center announced the first patient has been treated at Sheba Medical Center with a CD19 CAR-T cell immunotherapy manufactured using Lonza’s Cocoon® Platform.
President Trump visited Volunteer Pastilles, LLC Lake Charles plant on Saturday, August 29, while he was in Lake Charles assessing the damage from Hurricane Laura.
The Society of Chemical Manufacturers & Affiliates (SOCMA) is pleased to announce it is returning to trade show ownership with the acquisition of the Specialty & Custom Chemicals Show, a trade show founded in 2019 and produced by Chemicals America.
Sun Chemical has organized a Corporate Sustainability Committee to further strengthen its approach to addressing the sustainability needs of the packaging industry.
Solvay signed a global distribution agreement with Strem Chemicals, Inc., a manufacturer of high-purity specialty products, to fulfill commercial sampling and research requests for its specialty phosphorus products.
Kodiak Sciences, a clinical-stage biopharmaceutical company specializing in novel ophthalmic therapies, and Lonza announced today that the companies have signed a long-term contract for manufacturing KSI-301, an Antibody Biopolymer Conjugate (ABC) that is a potential first-line treatment for retinal vascular diseases.
